Join
Live feed
·
PRReleasevia Quantisnow
AgomAb Therapeutics NV logo

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

ByQuantisnow·Wall Street's wire, on your screen.
AGMB· AgomAb Therapeutics NV
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGMB (AgomAb Therapeutics NV) and more on Quantisnow.